The Proteomics Shared Resource offers state-of-the-art, user-friendly mass spectrometry-based resources to support Cancer Center members. In addition to making available facilities and services, the Core enables education, methods development and new applications, all designed to meet the rapidly evolving needs of researchers in cancer research. The Core operates under the direction of Dr. Allis Chien, with oversight by an interdisciplinary faculty advisory committee. It occupies 2200 sq ft of space in a conveniently accessible central campus location, and employs four staff scientists in addition to Dr. Chien. Currently, the core houses six mass spectrometers and associated instrumentation;these include single quad, ion trap, triple quad, and Q-Tof mass spectrometers, as well as 2-D nano-LC systems and nanospray robots. In-house proteomics data processing capabilities include Sequest, Mascot, Scaffold, and MaxQuant. Annual operating costs are approximately $400,000;as an A21-compliant cost center, the facility operates on a cost-recovery basis, with ongoing expenses recovered primarily through user fees. In 2008, the labs of 32 Cancer Center members comprised 52% of the facility's user base, up from 40% in 2007. Future goals include the implementation of new MS instrumentation, expansion of quantitative proteomics services, and enhancement of data processing capabilities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA124435-06
Application #
8375610
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
6
Fiscal Year
2012
Total Cost
$40,105
Indirect Cost
$4
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Patel, Manali I; Sundaram, Vandana; Desai, Manisha et al. (2018) Effect of a Lay Health Worker Intervention on Goals-of-Care Documentation and on Health Care Use, Costs, and Satisfaction Among Patients With Cancer: A Randomized Clinical Trial. JAMA Oncol 4:1359-1366
Trieu, Vanessa; Pinto, Harlan; Riess, Jonathan W et al. (2018) Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck. Oncologist 23:764-e86
Kuonen, François; Surbeck, Isabelle; Sarin, Kavita Y et al. (2018) TGF?, Fibronectin and Integrin ?5?1 Promote Invasion in Basal Cell Carcinoma. J Invest Dermatol 138:2432-2442
Gee, Marvin H; Han, Arnold; Lofgren, Shane M et al. (2018) Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes. Cell 172:549-563.e16
Malta, Tathiane M; Sokolov, Artem; Gentles, Andrew J et al. (2018) Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell 173:338-354.e15
Banerjee, Imon; Gensheimer, Michael Francis; Wood, Douglas J et al. (2018) Probabilistic Prognostic Estimates of Survival in Metastatic Cancer Patients (PPES-Met) Utilizing Free-Text Clinical Narratives. Sci Rep 8:10037
Thorsson, Vésteinn; Gibbs, David L; Brown, Scott D et al. (2018) The Immune Landscape of Cancer. Immunity 48:812-830.e14
Rogers, Zoë N; McFarland, Christopher D; Winters, Ian P et al. (2018) Mapping the in vivo fitness landscape of lung adenocarcinoma tumor suppression in mice. Nat Genet 50:483-486
Nair, Viswam S; Sundaram, Vandana; Desai, Manisha et al. (2018) Accuracy of Models to Identify Lung Nodule Cancer Risk in the National Lung Screening Trial. Am J Respir Crit Care Med 197:1220-1223
She, Richard; Jarosz, Daniel F (2018) Mapping Causal Variants with Single-Nucleotide Resolution Reveals Biochemical Drivers of Phenotypic Change. Cell 172:478-490.e15

Showing the most recent 10 out of 322 publications